dc.contributor.author |
Blein, Sophie
|
|
dc.contributor.author |
Bardel, Claire
|
|
dc.contributor.author |
Danjean, Vincent
|
|
dc.contributor.author |
McGuffog, Lesley
|
|
dc.contributor.author |
Healey, Sue
|
|
dc.contributor.author |
Barrowdale, Daniel
|
|
dc.contributor.author |
Lee, Andrew
|
|
dc.contributor.author |
Dennis, Joe
|
|
dc.contributor.author |
Kuchenbaecker, Karoline B.
|
|
dc.contributor.author |
Soucy, Penny
|
|
dc.contributor.author |
Terry, Mary Beth
|
|
dc.contributor.author |
Chung, Wendy K.
|
|
dc.contributor.author |
Goldgar, David E.
|
|
dc.contributor.author |
Buys, Saundra S.
|
|
dc.contributor.author |
Breast Cancer Family Registry
|
|
dc.contributor.author |
Janavicius, Ramunas
|
|
dc.contributor.author |
Tihomirova, Laima
|
|
dc.contributor.author |
Tung, Nadine
|
|
dc.contributor.author |
Dorfling, Cecilia Maria
|
|
dc.contributor.author |
Jansen van Rensburg, Elizabeth
|
|
dc.contributor.author |
Neuhausen, Susan L.
|
|
dc.contributor.author |
Ding, Yuan Chun
|
|
dc.contributor.author |
Gerdes, Anne-Marie
|
|
dc.contributor.author |
Ejlertsen, Bent
|
|
dc.contributor.author |
Nielsen, Finn C.
|
|
dc.contributor.author |
Hansen, Thomas V.O.
|
|
dc.contributor.author |
Osorio, Ana
|
|
dc.contributor.author |
Benitez, Javier
|
|
dc.contributor.author |
Conejero, Raquel Andres
|
|
dc.contributor.author |
Segota, Ena
|
|
dc.contributor.author |
Weitzel, Jeffrey N.
|
|
dc.contributor.author |
Thelander, Margo
|
|
dc.contributor.author |
Peterlongo, Paolo
|
|
dc.contributor.author |
Radice, Paolo
|
|
dc.contributor.author |
Pensotti, Valeria
|
|
dc.contributor.author |
Dolcetti, Riccardo
|
|
dc.contributor.author |
Bonanni, Bernardo
|
|
dc.contributor.author |
Peissel, Bernard
|
|
dc.contributor.author |
Zaffaroni, Daniela
|
|
dc.contributor.author |
Scuvera, Giulietta
|
|
dc.contributor.author |
Manoukian, Siranoush
|
|
dc.contributor.author |
Varesco, Liliana
|
|
dc.contributor.author |
Capone, Gabriele L
|
|
dc.contributor.author |
Papi, Laura
|
|
dc.contributor.author |
Ottini, Laura
|
|
dc.contributor.author |
Yannoukakos, Drakoulis
|
|
dc.contributor.author |
Konstantopoulou, Irene
|
|
dc.contributor.author |
Garber, Judy
|
|
dc.contributor.author |
Hamann, Ute
|
|
dc.contributor.author |
Donaldson, Alan
|
|
dc.contributor.author |
Brady, A.
|
|
dc.contributor.author |
Brewer, Carole
|
|
dc.contributor.author |
Foo, Claire
|
|
dc.contributor.author |
Evans, D. Gareth
|
|
dc.contributor.author |
Frost, Debra
|
|
dc.contributor.author |
Eccles, Diana M.
|
|
dc.contributor.author |
EMBRACE
|
|
dc.contributor.author |
Douglas, Fiona
|
|
dc.contributor.author |
Cook, Jackie
|
|
dc.contributor.author |
Adlard, Julian
|
|
dc.contributor.author |
Barwell, Julian
|
|
dc.contributor.author |
Walker, Lisa
|
|
dc.contributor.author |
Izatt, Louise
|
|
dc.contributor.author |
Side, Lucy E.
|
|
dc.contributor.author |
Kennedy, M.J.
|
|
dc.contributor.author |
Tischkowitz, Marc
|
|
dc.contributor.author |
Rogers, Mark T.
|
|
dc.contributor.author |
Porteous, Mary E.
|
|
dc.contributor.author |
Morrison, Patrick J.
|
|
dc.contributor.author |
Platte, Radka
|
|
dc.contributor.author |
Eeles, Rosalind A.
|
|
dc.contributor.author |
Davidson, Rosemarie
|
|
dc.contributor.author |
Hodgson, Shirley
|
|
dc.contributor.author |
Cole, Trevor
|
|
dc.contributor.author |
Godwin, Andrew K.
|
|
dc.contributor.author |
Isaacs, Claudine
|
|
dc.contributor.author |
Claes, Kathleen
|
|
dc.contributor.author |
De Leeneer, Kim
|
|
dc.contributor.author |
Meindl, Alfons
|
|
dc.contributor.author |
Gehrig, Andrea
|
|
dc.contributor.author |
Wappenschmidt, Barbara
|
|
dc.contributor.author |
Sutter, Christian
|
|
dc.contributor.author |
Engel, Christoph
|
|
dc.contributor.author |
Niederacher, Dieter
|
|
dc.contributor.author |
Steinemann, Doris
|
|
dc.contributor.author |
Plendl, Hansjoerg
|
|
dc.contributor.author |
Kast, Karin
|
|
dc.contributor.author |
Rhiem, Kerstin
|
|
dc.contributor.author |
Ditsch, Nina
|
|
dc.contributor.author |
Arnold, Norbert
|
|
dc.contributor.author |
Varon-Mateeva, Raymonda
|
|
dc.contributor.author |
Schmutzler, Rita Katharina
|
|
dc.contributor.author |
Preisler-Adams, Sabine
|
|
dc.contributor.author |
Markov, Nadja Bogdanova
|
|
dc.contributor.author |
Wang-Gohrke, Shan
|
|
dc.contributor.author |
De Pauw, Antoine
|
|
dc.contributor.author |
Lefol, Cedrick
|
|
dc.contributor.author |
Lasset, Christine
|
|
dc.contributor.author |
Leroux, Dominique
|
|
dc.contributor.author |
Rouleau, Etienne
|
|
dc.contributor.author |
Damiola, Francesca
|
|
dc.contributor.author |
GEMO Study Collaborators
|
|
dc.contributor.author |
Dreyfus, Helene
|
|
dc.contributor.author |
Barjhoux, Laure
|
|
dc.contributor.author |
Golmard, Lisa
|
|
dc.contributor.author |
Uhrhammer, Nancy
|
|
dc.contributor.author |
Bonadona, Valerie
|
|
dc.contributor.author |
Sornin, Valerie
|
|
dc.contributor.author |
Bignon, Yves-Jean
|
|
dc.contributor.author |
Carter, Jonathan
|
|
dc.contributor.author |
Van Le, Linda
|
|
dc.contributor.author |
Piedmonte, Marion
|
|
dc.contributor.author |
DiSilvestro, Paul A.
|
|
dc.contributor.author |
De la Hoya, Miguel
|
|
dc.contributor.author |
Caldes, Trinidad
|
|
dc.contributor.author |
Nevanlinna, Heli
|
|
dc.contributor.author |
Aittomaki, Kristiina
|
|
dc.contributor.author |
Jager, Agnes
|
|
dc.contributor.author |
Van den Ouweland, Ans M.W.
|
|
dc.contributor.author |
Kets, Carolien M.
|
|
dc.contributor.author |
Aalfs, Cora M.
|
|
dc.contributor.author |
Van Leeuwen, Flora E.
|
|
dc.contributor.author |
Hogervorst, Frans B.L.
|
|
dc.contributor.author |
Meijers-Heijboer, Hanne E.J.
|
|
dc.contributor.author |
HEBON
|
|
dc.contributor.author |
Oosterwijk, Jan
|
|
dc.contributor.author |
Van Roozendaal, Kees E.P.
|
|
dc.contributor.author |
Rookus, Matti A.
|
|
dc.contributor.author |
Devilee, Peter
|
|
dc.contributor.author |
Van der Luijt, Rob B
|
|
dc.contributor.author |
Olah, Edith
|
|
dc.contributor.author |
Diez, Orland
|
|
dc.contributor.author |
Teule, Alex
|
|
dc.contributor.author |
Lazaro, Conxi
|
|
dc.contributor.author |
Blanco, Ignacio
|
|
dc.contributor.author |
Del Valle, Jesus
|
|
dc.contributor.author |
Jakubowska, Anna
|
|
dc.contributor.author |
Sukiennicki, Grzegorz
|
|
dc.contributor.author |
Gronwald, Jacek
|
|
dc.contributor.author |
Lubinski, Jan
|
|
dc.contributor.author |
Durda, Katarzyna
|
|
dc.contributor.author |
Jaworska-Bieniek, Katarzyna
|
|
dc.contributor.author |
Agnarsson, Bjarni A.
|
|
dc.contributor.author |
Maugard, Christine
|
|
dc.contributor.author |
Amadori, Alberto
|
|
dc.contributor.author |
Montagna, Marco
|
|
dc.contributor.author |
Teixeira, Manuel R.
|
|
dc.contributor.author |
Spurdle, Amanda B.
|
|
dc.contributor.author |
Foulkes, William
|
|
dc.contributor.author |
Olswold, Curtis
|
|
dc.contributor.author |
Lindor, Noralane M.
|
|
dc.contributor.author |
Pankratz, Vernon S.
|
|
dc.contributor.author |
Szabo, Csilla I.
|
|
dc.contributor.author |
Lincoln, Anne
|
|
dc.contributor.author |
Jacobs, Lauren
|
|
dc.contributor.author |
Corines, Marina J.
|
|
dc.contributor.author |
Robson, Mark E.
|
|
dc.contributor.author |
Vijai, Joseph
|
|
dc.contributor.author |
Berger, Andreas
|
|
dc.contributor.author |
Fink-Retter, Anneliese
|
|
dc.contributor.author |
Singer, Christian F.
|
|
dc.contributor.author |
Rappaport, Christine
|
|
dc.contributor.author |
Kaulich, D.G.
|
|
dc.contributor.author |
Pfeiler, Georg
|
|
dc.contributor.author |
Tea, Muy-Kheng M.
|
|
dc.contributor.author |
Greene, Mark H.
|
|
dc.contributor.author |
Mai, Phuong L.
|
|
dc.contributor.author |
Rennert, Gad
|
|
dc.contributor.author |
Imyanitov, Evgeny N.
|
|
dc.contributor.author |
Mulligan, Anna Marie
|
|
dc.contributor.author |
Glendon, Gord
|
|
dc.contributor.author |
Andrulis, Irene L.
|
|
dc.contributor.author |
Tchatchou, Sandrine
|
|
dc.contributor.author |
Toland, Amanda Ewart
|
|
dc.contributor.author |
Pedersen, Inge Sokilde
|
|
dc.contributor.author |
Thomassen, Mads
|
|
dc.contributor.author |
Kruse, Torben A
|
|
dc.contributor.author |
Jensen, Uffe Birk
|
|
dc.contributor.author |
Caligo, Maria A.
|
|
dc.contributor.author |
Friedman, Eitan
|
|
dc.contributor.author |
Zidan, Jamal
|
|
dc.contributor.author |
Laitman, Yael
|
|
dc.contributor.author |
Lindblom, Annika
|
|
dc.contributor.author |
Melin, B.
|
|
dc.contributor.author |
Arver, Brita
|
|
dc.contributor.author |
Loman, Niklas
|
|
dc.contributor.author |
Rosenquist, Richard
|
|
dc.contributor.author |
Olopade, Olufunmilayo I.
|
|
dc.contributor.author |
Nussbaum, Robert L.
|
|
dc.contributor.author |
Ramus, Susan J.
|
|
dc.contributor.author |
Nathanson, Katherine L.
|
|
dc.contributor.author |
Domchek, Susan M.
|
|
dc.contributor.author |
Rebbeck, Timothy R.
|
|
dc.contributor.author |
Arun, Banu K.
|
|
dc.contributor.author |
Mitchell, Gillian
|
|
dc.contributor.author |
Karlan, Beth Y.
|
|
dc.contributor.author |
Lester, Jenny
|
|
dc.contributor.author |
Orsulic, Sandra
|
|
dc.contributor.author |
Stoppa-Lyonnet, Dominique
|
|
dc.contributor.author |
Thomas, Gilles
|
|
dc.contributor.author |
Simard, Jacques
|
|
dc.contributor.author |
Couch, Fergus J.
|
|
dc.contributor.author |
Offit, Kenneth
|
|
dc.contributor.author |
Easton, Douglas F.
|
|
dc.contributor.author |
Chenevix-Trench, Georgia
|
|
dc.contributor.author |
Antoniou, Antonis C.
|
|
dc.contributor.author |
Mazoyer, Sylvie
|
|
dc.contributor.author |
Phelan, Catherine M.
|
|
dc.contributor.author |
Sinilnikova, Olga M.
|
|
dc.contributor.author |
Cox, David G.
|
|
dc.date.accessioned |
2015-11-26T12:41:00Z |
|
dc.date.available |
2015-11-26T12:41:00Z |
|
dc.date.issued |
2015-04-25 |
|
dc.description |
Additional file 1: List of ethical committees that approved the
access to the data analyzed in this study. |
en_ZA |
dc.description |
Additional file 2: SNPs selected for downstream analyses. |
en_ZA |
dc.description |
Additional file 3: Description and results of the procedure used to
estimate the accuracy of our haplogroup inference methodology. |
en_ZA |
dc.description |
Additional file 4: Absolute and relative frequencies of imputed
haplogroups by population. Table containing absolute and relative
frequencies of imputed haplogroups for BRCA1 and BRCA2 mutation carriers. |
en_ZA |
dc.description |
Additional file 6: Details of haplogroups inference results for
subclade T. |
en_ZA |
dc.description |
Additional file 7: Methods used to compute coevolution index. |
en_ZA |
dc.description |
Additional file 5: Correlated evolution index for all non-monomorphic
sites observed in short haplotype sequences of subclade T. Table
containing correlated evolution index for all non-monomorphic sites
observed in short haplotypes sequences of subclade T. |
en_ZA |
dc.description.abstract |
INTRODUCTION : Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of
breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused
by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations
affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial
haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background
can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that
mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers.
METHODS : We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of
Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference
and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference
mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals.
RESULTS : We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of
clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent
haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to
0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has
demonstrated an inverse association with familial breast cancer risk.
CONCLUSIONS : This study illustrates how original approaches such as the phylogeny-based method we used can empower
classical molecular epidemiological studies aimed at identifying association or risk modification effects. |
en_ZA |
dc.description.librarian |
am2015 |
en_ZA |
dc.description.sponsorship |
Higher-level funding: The COGS project is funded through a European
Commission Seventh Framework Program grant (agreement number 223175:
HEALTH-F2-2009-223175). The CIMBA data management and data analysis
were supported by Cancer Research UK grants C12292/A11174 and
C1287/A10118. SH is supported by a National Health and Medical
Research Council (NHMRC) program grant (to GCT).
Individual researcher support: ACA is a Cancer Research UK Senior Cancer
Research Fellow (C12292/A11174). DFE is a Principal Research Fellow of
Cancer Research UK. GC, MCS and IC are supported by the National Health
and Medical Research Council (NHMRC). BK holds an American Cancer
Society Early Detection Professorship (SIOP-06-258-01-COUN). MHG and PLM
were supported by funding from the Intramural Research Program of the
National Cancer Institute, National Institutes of Health. OIO is an American
Cancer Society Clinical Research Professor. JS is Chairholder of the Canada
Research Chair in Oncogenetics.
Funding of constituent studies: The Breast Cancer Family Registry (BCFR) was
supported by grant UM1 CA164920 from the National Cancer Institute,
National Institutes of Health. The content of this article does not necessarily
reflect the views or policies of the National Cancer Institute or any of the
collaborating centers in the BCFR, nor does mention of trade names,
commercial products or organizations imply endorsement by the US
Government or the BCFR. The Baltic Familial Breast Ovarian Cancer
Consortium (BFBOCC) is partly supported by Lithuania (BFBOCC-LT):
Research Council of Lithuania grant LIG-07/2012; BFBOCC-LV (Latvia) is
partly supported by LSC grant 10.0010.08 and in part by a grant from the
European Social Fund number 2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016
and the Liepāja City Council, Liepāja, Latvia; Beth Israel Deaconess Medical
Center Cancer Center is supported by the Breast Cancer Research Foundation; BRCA-gene mutations and breast cancer in South African women (BMBSA) was
supported by grants from the Cancer Association of South Africa (CANSA) to
Elizabeth J van Rensburg; SLN (Beckman Research Institute, City of Hope,
Duarte, CA, USA) was partially supported by the Morris and Horowitz Families
Professorship in Cancer Etiology and Outcomes Research; the Copenhagen
Breast Cancer Study (CBCS) was supported by the NEYE Foundation; the
Spanish National Cancer Research Center (Centro Nacional de Investigaciones
Oncológicas (CNIO)) was partially supported by the Spanish Association against
Cancer (Asociación Española Contra el Cáncer AECC08), Thematic Network Cooperative Research in Cancer (Red Temática Investigación Cooperativa en
Cáncer (RTICC), Centro de Investigación Cáncer, Salamanca, Spain) RTICC
06/0020/1060, Spanish Ministry of Science and Innovation grants FIS PI08 1120
(Fondo de Investigación Sanitaria (FIS)) and SAF2010-20493, and the Fundación
Mutua Madrileña (FMMA); the City of Hope Clinical Cancer Genetics Community
Network and the Hereditary Cancer Research Registry (COH-CCGCRN), supported
in part by award number RC4CA153828 (Principal Investigator: JNW) from the
National Cancer Institute and the Office of the Director, National Institutes of
Health. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella, Italy (CONSIT
Team): Funds from Italian citizens who allocated the “5 × 1,000” share of
their tax payment in support of the Fondazione IRCCS Istituto Nazionale
Tumori, according to Italian laws (Istituto Nazionale dei Tumori (INT)
institutional strategic project “5 × 1,000”) (to SM); the Italian Association for
Cancer Research (AIRC) (to LO); National Centre for Scientific Research
“Demokritos” has been cofinanced by the European Union (European Social
Fund (ESF)) and Greek national funds through the “Education and Lifelong
Learning” operational program of the National Strategic Reference
Framework (NSRF) – Research Funding Program of the General Secretariat
for Research and Technology: ARISTEIA; “Heracleitus II: Investing in
knowledge society through the European Social Fund”; the DKFZ study was
supported by the Deutsches Krebsforschungszentrum (DKFZ);
Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE) is
supported by Cancer Research UK grants C1287/A10118 and C1287/A11990;
DGE and FL are supported by a National Institute for Health Research (NIHR) grant to the Biomedical Research Centre, Manchester, UK; the investigators at
The Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust are supported by an NIHR grant to the Biomedical Research Centre at
The Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust, London; RE and EB are supported by Cancer Research UK grant
C5047/A8385; Kansas University Medical Center: The authors acknowledge
support from The University of Kansas Cancer Center (P30 CA168524) and
the Kansas Bioscience Authority Eminent Scholar Program; AKG was funded
by grants 5U01 CA113916 and R01 CA140323 and by the Chancellors
Distinguished Chair in Biomedical Sciences Professorship; The German
Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported
by German Cancer Aid (grant 109076 (to RKS) and by the Center for
Molecular Medicine Cologne (CMMC); GC-HBOC is deeply grateful to
Dr Sabine Preisler-Adam for providing information and samples; the GEMO
Study was supported by the Ligue National Contre le Cancer; the Association
“Le cancer du sein, parlons-en!” Award; and the Canadian Institutes of Health
Research for the CIHR Team in Familial Risks of Breast Cancer program;
G-FAST: KDL is supported by GOA grant BOF10/GOA/019 (Ghent University)
and spearhead financing of Ghent University Hospital; the Gynecologic
Oncology Group (GOG) was supported by National Cancer Institute grants to
the GOG Administrative Office and Tissue Bank (grant CA 27469), the GOG
Statistical and Data Center (grant CA 37517) and GOG’s Cancer Prevention
and Control Committee (grant CA 101165); HCSC was supported by grants
RD12/00369/0006 and 12/00539 from Instituto de Salud Carlos III (ISCIII),
Madrid, Spain, partially supported by European Regional Development Fund
(Fonds européen de développement régional (FEDER)) funds; the Helsinki
Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528),
the Finnish Cancer Society and the Sigrid Juselius Foundation; HEBON is
supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088
and NKI2007-3756, the Netherlands Organization of Scientific Research
grant NWO 91109024, the Pink Ribbon grant 110005 and Biobanking and
Molecular Resource Infrastructure (BBMRI) grant NWO 184.021.007/CP46;
HEBON thanks the registration teams of the Comprehensive Cancer Centre
Netherlands and Comprehensive Centre South (together the Netherlands
Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data
collection; the High Risk Breast Cancer Program (HRBCP) is supported by the
Hong Kong Hereditary Breast Cancer Family Registry and the Dr Ellen Li
Charitable Foundation, Hong Kong; the Hungarian Breast and Ovarian
Cancer Study (HUNBOCS) was supported by Hungarian Research and
Technological Innovation Fund (KTIA)/Hungarian Scientific Research Fund
(Országos Tudományos Kutatási Alapprogramok (OTKA)) research grants
KTIA-OTKA CK-80745 and KTIA-OTKA K-112228; Institut Català d’Oncologia
(ICO): contract grant sponsor: Asociación Española Contra el Cáncer; Spanish
Health Research Foundation; Ramón Areces Foundation; Instituto de Salud Carlos III (ISCIII); Catalan Health Institute; and Autonomous Government of
Catalonia; contract grant numbers ISCIIIRETIC RD06/0020/1051, PI09/02483,
PI10/01422, PI10/00748, PI13/00285, PI13/00189 2009SGR290 and PI13/00189
2009SGR283; the International Hereditary Cancer Center (Department of
Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland)
was supported by grant PBZ_KBN_122/P05/2004; Landspitali – The National
University Hospital of Iceland was supported by the Icelandic Association
“Walking for Breast Cancer Research” and by the Landspitali University
Hospital Research Fund; the Interdisciplinary Health Research Internal Team
Breast Cancer Susceptibility Study (INHERIT) was supported by the Canadian
Institutes of Health Research (CIHR) for the “CIHR Team in Familial Risks of
Breast Cancer” program, Canadian Breast Cancer Research Alliance grant
019511 and Ministry of Economic Development, Innovation and Export Trade
grant PSR-SIIRI-701; the Istituto Oncologico Veneto Hereditary Breast and
Ovarian Cancer Study (IOVHBOCS) is supported by the Ministero della Salute
and a “5 × 1,000” Istituto Oncologico Veneto grant; the Portuguese Oncology
Institute–Porto Breast Cancer Study (IPOBCS) was supported in part by Liga
Portuguesa Contra o Cancro; kConFab is supported by a grant from the
National Breast Cancer Foundation and previously by the National Health
and Medical Research Council (NHMRC), the Queensland Cancer Fund, the
Cancer Councils of New South Wales, Victoria, Tasmania and South
Australia, and the Cancer Foundation of Western Australia; the Mayo Clinic
is supported by National Institutes of Health (NIH) grants CA 116167, CA
128978 and CA 176785 through the National Cancer Institute (NCI), an NCI
Specialized Program of Research Excellence (SPORE) in Breast Cancer
(CA116201), a US Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), a grant from the Breast Cancer Research Foundation,
a generous gift from the David F and Margaret T Grohne Family Foundation
and the Ting Tsung and Wei Fong Chao Foundation; McGill University Jewish
General Hospital Weekend to End Breast Cancer, Quebec Ministry of
Economic Development, Innovation and Export Trade; Modifier Study of
Quantitative Effects on Disease (ModSQuaD) was supported by the Ministry
of Health of the Czech Republic to Masaryk Memorial Cancer Institute (MH
CZ – DRO) (MMCI 00209805) and by the European Regional Development
Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/
2.1.00/03.0101) (to LF), and by Charles University in Prague project
UNCE204024 (MZ); Memorial Sloan Kettering Cancer Center (MSKCC) is
supported by grants from the Breast Cancer Research Foundation and
Robert and Kate Niehaus Clinical Cancer Genetics Initiative; National Cancer
Institute, National Institutes of Health: The research of MHG and PLM was
supported by the Intramural Research Program of the National Cancer Institute
and by support services contracts N02-CP-11019-50 and N02-CP-65504 with
Westat, Inc, Rockville, MD, USA; the National Israeli Cancer Control Center (NICCC)
is supported by Clalit Health Services in Israel; some of its activities are supported
by the Israel Cancer Association and the Breast Cancer Research Foundation
(BCRF), New York, NY, USA; NN Petrov Institute of Oncology has been supported
by the Russian Federation for Basic Research (grants 11-04-00227, 12-04-00928
and 12-04-01490) and the Federal Agency for Science and Innovations, Russia
(contract 02.740.11.0780); The Ohio State University Clinical Cancer Genetics
(OSUCCG) is supported by The Ohio State University Comprehensive Cancer
Center; the Pisa Breast Cancer Study (PBCS) was supported by Istituto
Toscano Tumori (ITT) grants 2011–2013; Sheba Medical Center was partially
funded through a grant from the Israel Cancer Association and funding for the
Israeli Inherited Breast Cancer Consortium; the Swedish Breast Cancer Study collaborators are supported by the Swedish Cancer Society; The
University of Chicago is supported by NCI Specialized Program of Research
Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996 and
1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the
Entertainment Industry Fund National Women’s Cancer Research Alliance and
the Breast Cancer Research Foundation; University of California, Los Angeles
Jonsson Comprehensive Cancer Center Foundation: Breast Cancer Research
Foundation; University of California, San Francisco Cancer Risk Program and
Helen Diller Family Comprehensive Cancer Center; UK Familial Ovarian
Cancer Registry (UKFOCR) was supported by a project grant from Cancer
Research UK (to Paul DP Pharoah); the University of Pennsylvania: National
Institutes of Health (NIH) grants R01 CA102776 and R01 CA083855; the
Breast Cancer Research Foundation; the Susan G Komen for the Cure,
Basser Center for BRCA; Victorian Familial Cancer Trials Group (VFCTG):
Victorian Cancer Agency, Cancer Australia, National Breast Cancer
Foundation; The Women’s Cancer Program (WCP) at the Samuel Oschin
Comprehensive Cancer Institute, Cedars-Sinai Medical Center, is funded by the American Cancer Society Early Detection Professorship
(SIOP-06-258-01-COUN).
GEMO Study: National Cancer Genetics Network UNICANCER Genetic Group,
France.
The Hereditary Breast and Ovarian Cancer Research Group Netherlands
(HEBON) coordinating center: Netherlands Cancer Institute, Amsterdam. |
en_ZA |
dc.description.uri |
http://breast-cancer-research.com |
en_ZA |
dc.identifier.citation |
Blein et al, 2015, 'An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers', Breast Cancer Research, vol. 17, art. no. 61, pp. 1-15. |
en_ZA |
dc.identifier.issn |
1465-5411 (print) |
|
dc.identifier.issn |
1465-542X (online) |
|
dc.identifier.other |
10.1186/s13058-015-0567-2 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/50958 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
BioMed Central |
en_ZA |
dc.rights |
© 2015 Blein et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License. |
en_ZA |
dc.subject |
Breast cancer |
en_ZA |
dc.subject |
Pathogenic mutations |
en_ZA |
dc.subject |
Mitochondria |
en_ZA |
dc.subject |
BRCA1 |
en_ZA |
dc.subject |
BRCA2 |
en_ZA |
dc.subject |
Deoxyribonucleic acid (DNA) |
en_ZA |
dc.title |
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
en_ZA |
dc.type |
Article |
en_ZA |